Roughly three months before the August 22 PDUFA date for deramiocel in Duchenne muscular dystrophyDuchenne muscular dystrophy, Capricor is fighting a legal war against the distributor it chose to commercialize the drug — and the outcome of that fight matters as much as the FDA decision itself. The company filed suit against NS Pharma on May 7 seeking rescission of the U.S. distribution agreement, alleging the pricing structure embedded in the deal makes it structurally impossible to serve Medicare, Medicaid, and privately insured patients. That is not a contractual dispute at the margins. That is a pre-launch admission that the commercialization architecture was broken before a single dose shipped.
The clinical foundation underneath this mess is genuinely strong. HOPE-3 met its primary endpoint on PUL v2.0 and cleared every Type I error-controlled secondary. The cardiac MRI subset showing reduced myocardial fibrosis by late gadolinium enhancement is the signal worth dwelling on — fibrosis in DMD is cumulative and irreversible, so a treatment demonstrating structural cardiac protection before patients lose function is a mechanistic argument that goes well beyond functional scores. Approximately 90 patients across open-label extensions have accumulated more than 800 infusions with a consistent tolerability record, which should ease labeling negotiations on the safety side. The FDA has issued a significant number of information requests, all addressed, and labeling discussions are expected to begin shortly — that sequencing suggests an active review rather than a stalled one.
The manufacturing picture is more advanced than the distribution situation deserves. The San Diego GMP facility passed its FDA Pre-License Inspection with all Form 483 observations resolved. A second-floor expansion targeting 2,000–2,500 patients annually at full capacity is underway, with FDA validation targeted for the first half of 2027. Capricor will begin stockpiling commercial doses once label guidance arrives. A $279 million cash position extends runway into Q4 2027, and a transferable Rare Pediatric Disease Priority Review Voucher upon approval adds a non-dilutive capital lever that could be worth $100 million or more depending on market conditions at the time of sale.
The single consequence to track is the preliminary injunction ruling against NS Pharma. If the court grants it before August 22, Capricor controls its own commercial launch from day one. If it doesn’t, approval becomes a clinical milestone attached to a distribution system the company itself calls patient-access-prohibitive.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
